RxDoctor Payments Data

Jon Lischke, MD

Gynecology · San Diego, CANPI 1447298773

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 24.8% of the total. Reporting peaked in 2019 at $1,328 and has fallen 64.5% since, to $471 in 2024.

$5,042in general payments, 2019–2025

Across 252 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Daiichi Sankyo Inc.$463
  • Amgen$384
  • Therapeuticsmd, Inc.$306
  • Astellas Pharma US Inc$230
  • Bayer$228
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,99799%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,042 in reported general payments places this provider in the 80th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$86,563
Medicare patients
227
Services billed
2,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol (Twice Weekly)Estradiol87$9,032
Estradiol176$5,605
ProgesteroneProgesterone, Micronized151$5,109
DottiEstradiol48$3,550
Estradiol (Once Weekly)Estradiol18$2,318
LyllanaEstradiol17$1,746
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet11$725
ValacyclovirValacyclovir Hcl22$713
Levothyroxine Sodium72$585
Terconazole17$422
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$379
Zolpidem Tartrate21$120
Alprazolam18$50

Paid to pharmacies, not to this prescriber.

Other gynecology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →